Effect of maprotiline on pentagastrin-stimulated acid secretion in man.
We have studied the effect of maprotiline, an antidepressant with a strong pronoradrenergic effect, on human gastric secretion. Twelve subjects (nine men and three women) entered the study; six had an active duodenal ulcer, and six were healthy volunteers. Each patient underwent two experiments with an interval of at least 48 h. In a randomized double-blind order, each patient received maprotiline or placebo intravenously during intravenous stimulation with pentagastrin (2 micrograms/kg/h). Thirty minutes after basal collection, pentagastrin was administered for 180 min by constant intravenous infusion. After 60 min placebo or maprotiline (1 mg/kg/h) was added to the intravenous infusion from the 60th to 120th min; thereafter 2 mg/kg/h were infused until the 180th min. Maprotiline infusion (2 mg/kg/h) inhibited significantly stimulated acid secretion in comparison with placebo in duodenal ulcer patients but not in healthy volunteers.
D000328:Adult; D000873:Anthracenes / Q000494:pharmacology*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000503:physiopathology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000494:pharmacology*; D008875:Middle Aged; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010418:Pentagastrin / Q000494:pharmacology*; D011897:Random Allocation; D012965:Sodium Chloride / Q000494:pharmacology
D000873:Anthracenes; D008376:Maprotiline; D012965:Sodium Chloride; D010418:Pentagastrin; D009638:Norepinephrine